Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALDH5A1 | P51649 | 3/20 | 0.40 |
| ▸ | ABAT | P80404 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29935588 | 1.00 | ERN1 (0.47) | ERN1KDM4ERAB9APTGS2ALDH1A1 | |
| SCHEMBL29955516 | 0.86 | KDM4E (0.47) | ERN1KDM4ERAB9APTGS2ALDH1A1 | |
| SCHEMBL6201297 | 0.79 | NR4A2 (0.56) | ERN1KDM4ERAB9AALDH1A1MEN1 | |
| SCHEMBL4585191 | 0.79 | SMN1; SMN2 (0.47) | ERN1KDM4ERAB9AALDH1A1MEN1 | |
| SCHEMBL18525595 | 0.79 | ERN1 (0.44) | ERN1KDM4ERAB9AMEN1KMT2A | |
| SCHEMBL4389687 | 0.79 | ALDH1A1 (0.40) | ERN1KDM4ERAB9APTGS2ALDH1A1 | |
| SCHEMBL732379 | 0.79 | ALDH1A1 (0.47) | ERN1KDM4ERAB9AALDH1A1MEN1 | |
| SCHEMBL29935762 | 0.79 | SMN1; SMN2 (0.47) | ERN1KDM4ERAB9AALDH1A1MEN1 | |
| SCHEMBL13591344 | 0.78 | KDM4E (0.39) | ERN1KDM4ERAB9APTGS2ALDH1A1 | |
| SCHEMBL4586321 | 0.78 | LMNA (0.57) | KDM4ERAB9AALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113164458-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-13 | — | — | CN | disclosed |
| CN-113164458-A | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-20080214455-A1 | Novel Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-09-04 | — | — | US | disclosed |
| EP-1879563-A4 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2008-07-16 | — | — | EP | disclosed |
| EP-1879563-A2 | NOVEL CHEMICAL COMPOUNDS | Smithkline Beecham Corporation (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006132739-A2 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-14 | — | — | WO | disclosed |
| US-7129356-B2 | Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-31 | — | — | US | disclosed |
| US-20060135769-A1 | Farnesyl transferase inhibiting 4-heterocyclyl-quinoline and quinazoline derivatives | ANGIBAUD PATRICK R | 2006-06-22 | — | — | US | disclosed |
| EP-1351954-B1 | FARNESYL TRANSFERASE INHIBITING 4-HETEROCYCLYL-QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2006-05-03 | — | — | EP | disclosed |
| EP-1347966-B1 | FARNESYL TRANSFERASE INHIBITING 4-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2006-03-08 | — | — | EP | disclosed |
| US-20040067968-A1 | Farnesyl transferase inhibiting 4-heterocyclyl quinoline and quinazoline | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-04-08 | — | — | US | disclosed |
| US-20040063944-A1 | Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-04-01 | — | — | US | disclosed |
| EP-1351954-A1 | FARNESYL TRANSFERASE INHIBITING 4-HETEROCYCLYL-QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-10-15 | — | — | EP | disclosed |
| EP-1347966-A1 | FARNESYL TRANSFERASE INHIBITING 4-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-10-01 | — | — | EP | disclosed |
| WO-2002051835-A1 | FARNESYL TRANSFERASE INHIBITING 4-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-07-04 | — | — | WO | disclosed |
| WO-2002051834-A1 | FARNESYL TRANSFERASE INHIBITING 4-HETEROCYCLYL-QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067968-A1 | Farnesyl transferase inhibiting 4-heterocyclyl quinoline and quinazoline | FNTA, FNTB, ACAT2 | ERN1 1227/4885KDM4E 2268/4885RAB9A 183/4885 |
| US-20040063944-A1 | Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives | FNTA, FNTB, CYP7A1 | ERN1 1274/4885KDM4E 2357/4885RAB9A 183/4885 |
| US-20080214455-A1 | Novel Chemical Compounds | HIPK3, HIPK1, HIPK4 | ERN1 619/4885KDM4E 2665/4885RAB9A 1181/4885 |
| US-20060135769-A1 | Farnesyl transferase inhibiting 4-heterocyclyl-quinoline and quinazoline derivatives | FNTA, FNTB, RABGGTB | ERN1 1251/4885KDM4E 2411/4885RAB9A 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.